References
- Lee JA, Roehrig CS, Butto ED. Cancer care cost trends in the United States: 1998 to 2012. Cancer. 2016;122:1078–1084.
- Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
- Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. JMCP. 2014;20:669–675.
- Streeter SB, Schwartzberg L, Husain N, et al. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. JOP. 2011;7:46s–51s.
- Yezefski T, Schwemm A, Lentz M, et al. Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. Semin Hematol. 2017;55:185–188.
- IQVIA Institute for Human Data Science. Global Oncology Trends 2018 Parsippany, NJ2018 [cited 2019 January 4]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2018.pdf
- Li P, Wong Y-N, Jahnke J, et al. Association of high cost sharing and targeted therapy initiation among elderly medicare patients with metastatic renal cell carcinoma. Cancer Med. 2018;7:75–86.
- Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. JCO. 2016;34:4323–4328.
- Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum. 2008;59:1519–1526.
- StCharles M, Bollu VK, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood. 2009;114:2209.
- Bibeau WS, Fu H, Taylor AD, et al. Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes. JMCP. 2016;22:1338–1347.
- Burley MH, Daratha KB, Tuttle K, et al. Connecting patients to prescription assistance programs: effects on emergency department and hospital utilization. JMCP. 2016;22:381–387.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703.
- Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275–4283.
- Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
- Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
- Chustecka Z. Price of new cancer drugs as high as market can bear: medscape; 2014 [cited 2017 Sep 26]. Available from: http://www.medscape.com/viewarticle/830145
- Elliot W, Chan J. Brigatinib tablets (alunbrig): AHC media; 2017 [cited 2017 October 17]. Available from: https://www.ahcmedia.com/articles/140851-brigatinib-tablets-alunbrig
- Levitan D. First-Line alectinib tops crizotinib in ALK-Positive NSCLC: cancer network; 2016 [cited 2017 Sep 26]. Available from: http://www.cancernetwork.com/lung-cancer/first-line-alectinib-tops-crizotinib-alk-positive-nsclc
- Novartis. About the Co-Pay Card; 2018 [cited 2018 Jul 25]. Available from: https://www.us.zykadia.com/patient-support/financial-resources/
- Pfizer Oncology Together. Financial assistance XALKORI (critonib); 2018 [cited 2018 July 25]. Available from: https://www.pfizeroncologytogether.com/patient/xalkori/patient-financial-assistance
- Takeda Oncology. Alunbrig co-pay card; 2017 [cited 2018 Jul 25]. Available from: https://sservices.trialcard.com/Coupon/Alunbrig
- Genentech. Referrals to the genentech biooncology co-pay card; 2018 [cited 2018 Jul 25]. Available from: https://www.genentech-access.com/hcp/brands/alecensa/find-patient-assistance/co-pay-cards.html
- Hess LM, Louder A, Winfree K, et al. Factors associated with adherence to and treatment duration of erlotinib among patients with non-small cell lung cancer. JMCP. 2017;23:643–652.
- Patel AK, Duh MS, Barghout V, et al. Real-world treatment patterns among patients with colorectal cancer treated with trifluridine/tipiracil and regorafenib. Clin Colorectal Cancer. 2018;17:e531–e539.
- Felder TM, Lal LS, Bennett CL, et al. Cancer patients’ use of pharmaceutical patient assistance programs in the outpatient pharmacy at a large tertiary cancer center. Community Oncol. 2011;8:279–286.
- Mitchell A, Muluneh B, Patel R, et al. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. J Oncol Pharm Pract. 2017;24:1078155217719585.
- Wong Y-N, Meeker C, Doyle J, et al. Human capital costs of obtaining oral anticancer medications. JCO. 2016;34:6506.
- Zullig LL, Wolf S, Vlastelica L, et al. The role of patient financial assistance programs in reducing costs for cancer patients. JMCP. 2017;23:407–411.
- Doshi JA, Li P, Huo H, et al. High cost sharing and specialty drug initiation under medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. Am J Manag Care. 2016;22:s78–s86.
- Doshi JA, Li P, Huo H, et al. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents. JCO. 2018;36:476–482.
- Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125:191–200.
- Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. JCO. 2011;29:2534–2542.
- Li G, Dai WR, Shao FC. Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2017;21:3496–3503.
- NCCN Guidelines Version 6; 2018. Non-small cell lung cancer: National Comprehensive Cancer Network; 2018 [cited 2018 Aug 24]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- Camidge DR, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK + NSCLC. JCO. 2018;26:9043–9043.
- Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med.. 2017;377:829–838.
- Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68:153–165.
- Nordstrom BL, Whyte JL, Stolar M, et al. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf. 2012;21:21–28.
- Neumann PJ, Palmer JA, Nadler E, et al. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff. 2010;29:196–202.
- Shen C, Zhao B, Liu L, et al. Financial burden for patients with chronic myeloid leukemia enrolled in medicare part D taking targeted oral anticancer medications. JOP. 2017;13:e152–e162.
- Erman M, Humer C. U.S. drug prices hit by insurer tactic against copay assistance: analysis. Reuters; 2 August 2018. Available from: https://www.reuters.com/article/us-usa-healthcare-drugpricing/u-s-drug-prices-hit-by-insurer-tactic-against-copay-assistance-analysis-idUSKCN1J2005
- Policy Strategies For Aligning Price And Value For Brand-Name Pharmaceuticals. Health Affairs Policy Options Paper, March 15, 2018. DOI: 10.1377/hpb20180216.92303